Development and application of a multi-component LC-MS/MS method for determination of designer benzodiazepines in urine
| Autor: | Anders Helander, Olof Beck, Madeleine Pettersson Bergstrand |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Drug
medicine.drug_class media_common.quotation_subject Clinical Biochemistry Urine Drug problem 01 natural sciences Biochemistry Analytical Chemistry 03 medical and health sciences Benzodiazepines 0302 clinical medicine Tandem Mass Spectrometry Lc ms ms medicine Humans 030216 legal & forensic medicine media_common Benzodiazepine Chromatography medicine.diagnostic_test Chemistry 010401 analytical chemistry Reproducibility of Results Cell Biology General Medicine Flubromazepam Reference Standards 0104 chemical sciences Immunoassay Flubromazolam medicine.drug |
| Zdroj: | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1035 |
| ISSN: | 1873-376X |
| Popis: | New psychoactive substances (NPS) have become an increasing drug problem in the past decade. For detection of NPS, new analytical methods have to be developed, and the methods also have to be updated regularly. This study aimed at developing a multi-component LC-MS/MS method for detection and quantification of 11 NPS of the benzodiazepine sub-class ("designer benzodiazepines") in urine specimens. The method involves dilution of urine with internal standard and hydrolysis of any glucuronide conjugated forms. Separation of the compounds was achieved on a BEH Phenyl column, followed by MS/MS detection in positive electrospray mode. Method validation was performed following the EMA guideline. The method was applied to study the occurrence of designer benzodiazepines in Sweden in 2014-2015, by analysis of 390 samples retrieved from a routine drug testing laboratory. In 40% of these samples, selected based on a positive immunoassay benzodiazepine screening but a negative MS confirmation for the standard set of prescription benzodiazepines, intake of designer benzodiazepines was revealed. These results stress the importance of using and updating confirmation methods to include the increasing number of designer benzodiazepines appearing on the NPS market. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect